Q1 2026 earnings call recap: guidance reaffirmed, small cell/fiber sale timeline, DISH litigation update, buybacks & debt plan—read now.
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients ...
The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
By introducing 5G, the INCM aims to accelerate the digitalization of the national economy and foster an environment where new ...
A new technology allows light to be "designed" into desired forms, potentially making AI and communication technologies ...
A small pilot suggests deep brain stimulation may reshape dysfunctional brain circuits to curb severe self-harming behavior ...
LC-MS/MS remains central for PFAS quantification because ESI efficiently ionizes strongly acidic, predominantly anionic PFAAs ...
A quantum spin liquid is a phase of matter in which the magnetic moments in a material do not align or freeze, even at ...
MapLight Therapeutics, Inc. (NASDAQ:MPLT) is one of the must-buy small cap stocks to buy. On April 7, TD Cowen analyst Joseph ...
About ENSPRYNG® (satralizumab) ENSPRYNG, which was developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. ENSPRYNG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results